Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

6(75.0%)

Phase 2

1(12.5%)

Early Phase 1

1(12.5%)

8Total

Phase 1(6)

Phase 2(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03034304Phase 1Terminated

A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors

Role: lead

NCT06277154Phase 2Recruiting

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Role: lead

NCT05952947Phase 1Recruiting

HRYZ-T101 Injection for HPV18 Positive Solid Tumor

Role: lead

NCT05787535Phase 1Unknown

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

Role: lead

NCT04074564Early Phase 1Unknown

MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

Role: lead

NCT05877651Phase 1Completed

MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.

Role: lead

NCT03393416Phase 1Unknown

A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor

Role: lead

NCT02026362Phase 1Suspended

Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).

Role: lead

All 8 trials loaded